Disclosed are chelates resulting from the complexation of bifunctional do2pa derivatives ligands of formula (I), wherein the substituents R.sup.1, R.sup.1′, R.sup.2, R.sup.2′, R.sup.3, R.sup.3′, L.sup.1, L.sup.1′, L.sup.2 and L.sup.2′ are defined as in the claims, with metallic cations, especially Pb(II) and Bi(III). Also disclosed are bifunctional do2pa derivatives ligands of formula (I), as well as the use of chelates in nuclear medicine and the use of ligands in cations detection or epuration of effluents.

##STR00001##

The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclosed herein are methods of the using the DOTA-haptens of the present technology in diagnostic imaging as well as pretargeted radioimmunotherapy.

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T.sub.1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T.sub.1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. .sup.86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T.sub.1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T.sub.1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. .sup.86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.

The present invention refers to a process for obtaining gadoterate meglumine from high purity tetraxetan (DOTA) which does not require the use of organic solvents and optimizes the conditions of the synthetic process. The tetraxetan from which the gadoterate meglumine is obtained by a synthetic process that includes a purification step in which at least one electrodialysis is performed. This procedure makes it possible to obtain a tetraxetan and a gadoterate meglumine with minimal amounts of impurities.

The present invention refers to a process for obtaining gadoterate meglumine from high purity tetraxetan (DOTA) which does not require the use of organic solvents and optimizes the conditions of the synthetic process. The tetraxetan from which the gadoterate meglumine is obtained by a synthetic process that includes a purification step in which at least one electrodialysis is performed. This procedure makes it possible to obtain a tetraxetan and a gadoterate meglumine with minimal amounts of impurities.

It is disclosed a method for preparing calteridol used as MRI contrast agents. It provides a method for preparing calteridol comprising: obtaining teridol represented by the following Formula 2 by reacting gadoteridol represented by the following Formula 1 with decomplexing agent; and obtaining calteridol represented by the following Formula 3 by reacting calcium ion with teridol represented by following Formula 2. ##STR00001##

It is disclosed a method for preparing calteridol used as MRI contrast agents. It provides a method for preparing calteridol comprising: obtaining teridol represented by the following Formula 2 by reacting gadoteridol represented by the following Formula 1 with decomplexing agent; and obtaining calteridol represented by the following Formula 3 by reacting calcium ion with teridol represented by following Formula 2. ##STR00001##

The present invention relates to new ionizing radiation-activatable derivatives, their preparation process and their therapeutic uses.

The present invention relates to new ionizing radiation-activatable derivatives, their preparation process and their therapeutic uses.